stockrowHalozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.
- Revenue
- +39.2%
- EPS
- +45.6%
- Free cash flow
- −58.6%
- Total debt
- +115.1%
Quarter to September 2026, against a year earlier
Follow HALO
Alert me
Halozyme Therapeutics, Inc. (HALO) Revenue
Halozyme Therapeutics, Inc.'s revenue for fiscal 2025 was $1.4B, up 37.6% from $1.0B in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.8B. Over the past ten years it has ranged from $135.1M (fiscal 2015) to $1.4B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 7 consecutive fiscal years. Halozyme Therapeutics, Inc. ranks 16th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $1.4B | 37.55% |
| FY2024 | $1.0B | 22.44% |
| FY2023 | $829.3M | 25.62% |
| FY2022 | $660.1M | 48.91% |
| FY2021 | $443.3M | 65.67% |
| FY2020 | $267.6M | 36.53% |
| FY2019 | $196.0M | 29.06% |
| FY2018 | $151.9M | (52.04%) |
| FY2017 | $316.6M | 115.84% |
| FY2016 | $146.7M | 8.61% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $493.0M | 2.49% |
| Jun 2026 | $481.0M | 27.68% |
| Mar 2026 | $376.7M | (16.61%) |
| Dec 2025 | $451.8M | 27.52% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| JAZZ Jazz Pharmaceuticals PLC compare | $4.7B |
| BMRN BioMarin Pharmaceutical Inc. compare | $3.7B |
| EXEL Exelixis, Inc. compare | $2.5B |
| HALO Halozyme Therapeutics, Inc. | $1.8B |
| TECH Bio-Techne Corp compare | $1.2B |
| ASND Ascendis Pharma A/S compare | $1.2B |
| BBIO BridgeBio Pharma, Inc. compare | $945.5M |
| KYMR Kymera Therapeutics, Inc. compare | $105.0M |
| SMMT Summit Therapeutics PLC compare | $705.0K |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on HALO
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement